Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADK | P55263 | 3/20 | 0.64 |
| ▸ | METTL3 | Q86U44 | 1/20 | 0.56 |
| ▸ | PRMT5 | O14744 | 3/20 | 0.52 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.52 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.50 |
| ▸ | DNMT3B | Q9UBC3 | 1/20 | 0.50 |
| ▸ | DPP4 | P27487 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14568614 | 0.90 | ADK (0.60) | ADKMETTL3PRMT5WDR77DNMT1 | |
| Tubercidin SCHEMBL8259 | 0.87 | ADK (0.82) | ADKDNMT1DNMT3BDPP4 | |
| Tubercidin SCHEMBL11239877 | 0.87 | ADK (0.82) | ADKDNMT1DNMT3BDPP4 | |
| Tubercidin SCHEMBL6063615 | 0.87 | ADK (0.82) | ADKDNMT1DNMT3BDPP4 | |
| Tubercidin SCHEMBL23982350 | 0.87 | ADK (0.82) | ADKDNMT1DNMT3BDPP4 | |
| Tubercidin SCHEMBL23982115 | 0.87 | ADK (0.82) | ADKDNMT1DNMT3BDPP4 | |
| Tubercidin SCHEMBL1652797 | 0.87 | ADK (0.82) | ADKDNMT1DNMT3BDPP4 | |
| Tubercidin SCHEMBL23351430 | 0.87 | ADK (0.82) | ADKDNMT1DNMT3BDPP4 | |
| Tubercidin SCHEMBL20938187 | 0.87 | ADK (0.82) | ADKDNMT1DNMT3BDPP4 | |
| Tubercidin SCHEMBL20419149 | 0.87 | ADK (0.82) | ADKDNMT1DNMT3BDPP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070185063-A1 | Seven-membered ring nucleosides | IDENIX PHARMACEUTICALS, INC. | 2007-08-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070185063-A1 | Seven-membered ring nucleosides | NSUN2, NSUN3, HAVCR2 | ADK 359/4885METTL3 80/4885PRMT5 1055/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.